Licochalcone-A sensitizes human esophageal carcinoma cells to TRAIL-mediated apoptosis by proteasomal degradation of XIAP

Hepato-Gastroenterology

Volumn 61, Issue 133, 2014, Pages 1229-1234

  Yang, Pengfei ^a   Tuo, Lei ^b   Wu, Qingquan ^b   Cao, Xiufeng ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b YANCHENG INSTITUTE OF TECHNOLOGY   (China)

Author keywords

Apoptosis; Esophageal carcinoma; Licochalone A; TRAIL; XIAP

Indexed keywords

CASPASE 3; LICOCHALCONE A; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEASOME; PROTEIN KINASE B; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; CHALCONE DERIVATIVE; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; XIAP PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ECAL09 CELL LINE; ENZYME ACTIVATION; ENZYME INACTIVATION; ESOPHAGUS CARCINOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TE1 CELL LINE; CARCINOMA; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; ENZYMOLOGY; ESOPHAGUS TUMOR; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; METABOLISM; PATHOLOGY; TIME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA; CELL LINE, TUMOR; CHALCONES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ESOPHAGEAL NEOPLASMS; HEK293 CELLS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-AKT; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84906983710     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge14408     Document Type: Article

References (28)

1. Wiley SR, Schooley K, Smolak PJ, et al.: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3(6): 673-82. (Pubitemid 26091143)
2. Ashkenazi A, Pai RC, Fong S, et al.: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104(2): 155-62.
3. Jiang L, Hao JL, Jin ML, et al.: Effect of Embelin on TRAIL receptor 2 mAb-induced apoptosis of TRAIL-resistant A549 non-small cell lung cancer cells. Asian Pac J Cancer Prev 2013; 14(10): 6115-20.
4. Wu GS: TRAIL as a target in anti-cancer therapy. Cancer Lett 2009, 285(1): 1-5.
5. Grünhagen DJ, Brunstein F, ten-Hagen TL, et al.: TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas. Cancer Treat Res 2004; 120: 65-79.
6. Kischkel FC, Lawrence DA, Chuntharapai A, et al.: Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000; 12(6): 611-20.
7. Srivastava RK: TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 2001; 3(6): 535-46.
8. Tsai WS, Yeow WS, Chua A, et al.: Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin. Mol Cancer Ther 2006; 5(12): 2977-90. (Pubitemid 46092039)
9. Lalaoui N, Morlé A, Mérino D, et al.: TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT. PLoS One 2011; 6(5): e19679.
10. Xu J, Zhou JY, Wei WZ and Wu GS. Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PLoS One 2010; 19(5): e10226.
11. Dan HC, Sun M, Kaneko S, et al.: Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 2004; 279(7): 5405-12. (Pubitemid 38220563)
12. Li XQ, Ke XZ and Wang YM: Treatment of malignant melanoma by downregulation of XIAP and overexpression of TRAIL with a conditionally replicating oncolytic adenovirus. Asian Pac J Cancer Prev 2012b; 13(4): 1471-6.
13. Ren W, Qiao Z, Wang H, et al.: Flavonoids: promising anticancer agents. Med Res Rev 2003; 23(4): 519-34. (Pubitemid 36706514)
14. Wesołowska O, Wiśniewski J, Sroda-Pomianek K, et al.: Multidrug resistance reversal and apoptosis induction in human colon cancer cells by some flavonoids present in citrus plants. J Nat Prod 2012; 75(11): 1896-902.
15. Quan HY, Baek NI and Chung SH: Licochalcone A prevents adipocyte differentiation and lipogenesis via suppression of peroxisome proliferator-activated receptor γ and sterol regulatory element-binding protein pathways. J Agric Food Chem 2012; 60(20): 5112-20.
16. Chu X, Ci X, Wei M, et al.: Licochalcone a inhibits lipopolysaccharide- induced inflammatory response in vitro and in vivo. J Agric Food Chem 2012; 60(15): 3947-54.
17. Kim SS, Lim J, Bang Y, et al.: Licochalcone E activates Nrf2/anti-oxidant response element signaling pathway in both neuronal and microglial cells: therapeutic relevance to neurodegenerative disease. J Nutr Biochem 2012; 23(10): 1314-23.
18. Lee CS, Kwak SW, Kim YJ, et al.: Guanylate cyclase activator YC-1 potentiates apoptotic effect of licochalcone A on human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathways. Eur J Pharmacol 2012; 683(1-3): 54-62.
19. Kim SH, Kim K, Kwagh JG, et al.: Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem 2004; 279(38): 40044-52. (Pubitemid 39258279)
20. Bodmer JL, Holler N, Reynard S, et al.: TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000; 2(4): 241-3.
21. Suliman A, Lam A, Datta R and Srivastava RK: Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 2001; 20(17): 2122-33. (Pubitemid 32424006)
22. Cummins JM, Kohli M, Rago C, et al.: X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res 2004; 64(9): 3006-8. (Pubitemid 38581397)
23. Kim KM and Lee YJ: Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathway. Oncogene 2005; 24(3): 355-66. (Pubitemid 40188584)
24. Chawla-Sarkar M, Bae SI, Reu FJ, et al.: Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2004; 11(8): 915-23. (Pubitemid 39139750)
25. Fu Y, Hsieh TC, Guo J, et al.: Licochalcone-A, a novel flavonoid isolated from licorice root (Glycyrrhiza glabra), causes G2 and late-G1 arrests in androgen-independent PC-3 prostate cancer cells. Biochem Biophys Res Commun 2004; 322(1): 263-70. (Pubitemid 39093864)
26. Osaki M, Oshimura M and Ito H: PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004; 9(6): 667-76. (Pubitemid 40941196)
27. Li B, Ren H, Yue P, et al.: The novel Akt inhibitor API-1 induces c-FLIP degradation and synergizes with TRAIL to augment apoptosis independent of Akt inhibition. Cancer Prev Res (Phila) 2012a; 5(4): 612-20.
28. Li SS, Tang QL, Wang SH, et al.: Simultaneously targeting Bcl-2 and Akt pathways reverses resistance of nasopharyngeal carcinoma to TRAIL synergistically. Tumori 2011; 97(6): 762-70.